Definitive Healthcare (NASDAQ:DH) Upgraded to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Definitive Healthcare (NASDAQ:DHGet Rating) from a sell rating to a hold rating in a report issued on Tuesday morning, Zacks.com reports.

According to Zacks, “Definitive Healthcare Corp. provides healthcare commercial intelligence. The company’s SaaS platform creates new paths in the healthcare market. Definitive Healthcare Corp. is based in FRAMINGHAM, Mass. “

DH has been the subject of a number of other reports. Canaccord Genuity Group raised Definitive Healthcare from a hold rating to a buy rating and decreased their price target for the company from $46.00 to $28.00 in a research report on Thursday, February 24th. Canaccord Genuity Group raised Definitive Healthcare from a hold rating to a buy rating in a research report on Thursday, February 24th. Morgan Stanley raised Definitive Healthcare from an equal weight rating to an overweight rating and decreased their price target for the company from $46.00 to $40.00 in a research report on Thursday, December 16th. Credit Suisse Group reduced their price objective on Definitive Healthcare from $30.00 to $24.00 and set a neutral rating for the company in a report on Thursday, February 24th. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on Definitive Healthcare from $21.00 to $26.00 and gave the company a hold rating in a report on Tuesday, April 5th. Eight investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of Hold and an average target price of $37.00.

Shares of Definitive Healthcare stock opened at $26.15 on Tuesday. Definitive Healthcare has a 52 week low of $18.15 and a 52 week high of $50.30. The business has a 50 day moving average price of $23.16 and a 200-day moving average price of $28.97. The company has a debt-to-equity ratio of 0.18, a current ratio of 3.77 and a quick ratio of 3.77.

Definitive Healthcare (NASDAQ:DHGet Rating) last issued its quarterly earnings data on Wednesday, February 23rd. The company reported $0.04 EPS for the quarter, topping the consensus estimate of $0.02 by $0.02. The company had revenue of $46.31 million during the quarter, compared to analysts’ expectations of $44.78 million. As a group, equities research analysts expect that Definitive Healthcare will post 0.11 EPS for the current year.

In related news, CFO Richard Douglas Booth purchased 2,374 shares of the business’s stock in a transaction dated Thursday, March 3rd. The stock was purchased at an average cost of $21.06 per share, with a total value of $49,996.44. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

A number of large investors have recently bought and sold shares of the stock. Norges Bank bought a new stake in Definitive Healthcare during the fourth quarter valued at $19,401,000. BlackRock Inc. boosted its stake in Definitive Healthcare by 50.4% during the fourth quarter. BlackRock Inc. now owns 2,256,587 shares of the company’s stock valued at $61,672,000 after buying an additional 756,587 shares during the period. Wells Fargo & Company MN boosted its stake in Definitive Healthcare by 1,110.4% during the fourth quarter. Wells Fargo & Company MN now owns 55,932 shares of the company’s stock valued at $1,529,000 after buying an additional 51,311 shares during the period. California State Teachers Retirement System purchased a new stake in Definitive Healthcare during the fourth quarter valued at about $173,000. Finally, Parametric Portfolio Associates LLC purchased a new stake in Definitive Healthcare during the fourth quarter valued at about $429,000. 97.34% of the stock is owned by institutional investors.

About Definitive Healthcare (Get Rating)

Definitive Healthcare Corp., together with its subsidiaries, provides healthcare commercial intelligence in the United States. Its solutions provide information on healthcare providers and their activities to help its customers in the area ranging from product development to go-to-market planning, and sales and marketing execution.

Recommended Stories

Get a free copy of the Zacks research report on Definitive Healthcare (DH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Definitive Healthcare (NASDAQ:DH)

Receive News & Ratings for Definitive Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definitive Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.